Lauren Nye1, Alfred Rademaker2, William J Gradishar2. 1. Northwestern University Feinberg School of Medicine, Chicago, IL. Electronic address: lnye@kumc.edu. 2. Northwestern University Feinberg School of Medicine, Chicago, IL.
Abstract
BACKGROUND: Counseling patients regarding the risk of future pregnancy on hormone receptor-positive breast cancer outcomes is difficult because of the minimal data and understanding of pregnancy on the breast environment. PATIENTS AND METHODS: The present retrospective analysis included 32 premenopausal women with a diagnosis of estrogen receptor-positive breast cancer from 2000 to 2010 and subsequent pregnancy within 5 years. The control cohort included 29 women matched for age and stage of breast cancer who had not become pregnant. RESULTS: No statistically significant difference was found in age, diagnosis, stage, grade, or HER2 status between the 2 groups. Of the 32 women in the pregnancy cohort and 29 women in the control cohort, 19 (63%) and 23 (82%) had received endocrine therapy (P = .25). The mean length of endocrine therapy was 42.3 months (range, 0-120 months) in the control cohort and 20.9 months (range, 0-72 months) in the pregnancy cohort (P = .008). Four women (14%) in the control cohort experienced breast cancer recurrence compared with 8 women (26%) in the pregnancy cohort (P = .34). The 5-year disease-free survival rate was 92% (95% confidence interval, 81%-100%) in the control cohort compared with 84% (95% CI, 72%-97%) in the pregnancy cohort. The difference was not statistically significant (P = .69). CONCLUSION: The results of the present study did not demonstrate poorer disease-free survival for premenopausal women with estrogen receptor-positive breast cancer who became pregnant within 5 years of diagnosis. Our study is unique because all included patients had estrogen receptor-positive disease and were offered adjuvant hormonal therapy. Further prospective investigation will be beneficial to patients and physicians as they discuss pregnancy as a key survivorship issue.
BACKGROUND: Counseling patients regarding the risk of future pregnancy on hormone receptor-positive breast cancer outcomes is difficult because of the minimal data and understanding of pregnancy on the breast environment. PATIENTS AND METHODS: The present retrospective analysis included 32 premenopausal women with a diagnosis of estrogen receptor-positive breast cancer from 2000 to 2010 and subsequent pregnancy within 5 years. The control cohort included 29 women matched for age and stage of breast cancer who had not become pregnant. RESULTS: No statistically significant difference was found in age, diagnosis, stage, grade, or HER2 status between the 2 groups. Of the 32 women in the pregnancy cohort and 29 women in the control cohort, 19 (63%) and 23 (82%) had received endocrine therapy (P = .25). The mean length of endocrine therapy was 42.3 months (range, 0-120 months) in the control cohort and 20.9 months (range, 0-72 months) in the pregnancy cohort (P = .008). Four women (14%) in the control cohort experienced breast cancer recurrence compared with 8 women (26%) in the pregnancy cohort (P = .34). The 5-year disease-free survival rate was 92% (95% confidence interval, 81%-100%) in the control cohort compared with 84% (95% CI, 72%-97%) in the pregnancy cohort. The difference was not statistically significant (P = .69). CONCLUSION: The results of the present study did not demonstrate poorer disease-free survival for premenopausal women with estrogen receptor-positive breast cancer who became pregnant within 5 years of diagnosis. Our study is unique because all included patients had estrogen receptor-positive disease and were offered adjuvant hormonal therapy. Further prospective investigation will be beneficial to patients and physicians as they discuss pregnancy as a key survivorship issue.
Authors: D Craig Allred; Stewart J Anderson; Soonmyung Paik; D Lawrence Wickerham; Iris D Nagtegaal; Sandra M Swain; Elefetherios P Mamounas; Thomas B Julian; Charles E Geyer; Joseph P Costantino; Stephanie R Land; Norman Wolmark Journal: J Clin Oncol Date: 2012-03-05 Impact factor: 44.544
Authors: Beth A Mueller; Michael S Simon; Dennis Deapen; Aruna Kamineni; Kathleen E Malone; Janet R Daling Journal: Cancer Date: 2003-09-15 Impact factor: 6.860
Authors: Olivia Pagani; Meredith M Regan; Barbara A Walley; Gini F Fleming; Marco Colleoni; István Láng; Henry L Gomez; Carlo Tondini; Harold J Burstein; Edith A Perez; Eva Ciruelos; Vered Stearns; Hervé R Bonnefoi; Silvana Martino; Charles E Geyer; Graziella Pinotti; Fabio Puglisi; Diana Crivellari; Thomas Ruhstaller; Eric P Winer; Manuela Rabaglio-Poretti; Rudolf Maibach; Barbara Ruepp; Anita Giobbie-Hurder; Karen N Price; Jürg Bernhard; Weixiu Luo; Karin Ribi; Giuseppe Viale; Alan S Coates; Richard D Gelber; Aron Goldhirsch; Prudence A Francis Journal: N Engl J Med Date: 2014-06-01 Impact factor: 91.245
Authors: Christina Davies; Hongchao Pan; Jon Godwin; Richard Gray; Rodrigo Arriagada; Vinod Raina; Mirta Abraham; Victor Hugo Medeiros Alencar; Atef Badran; Xavier Bonfill; Joan Bradbury; Michael Clarke; Rory Collins; Susan R Davis; Antonella Delmestri; John F Forbes; Peiman Haddad; Ming-Feng Hou; Moshe Inbar; Hussein Khaled; Joanna Kielanowska; Wing-Hong Kwan; Beela S Mathew; Indraneel Mittra; Bettina Müller; Antonio Nicolucci; Octavio Peralta; Fany Pernas; Lubos Petruzelka; Tadeusz Pienkowski; Ramachandran Radhika; Balakrishnan Rajan; Maryna T Rubach; Sera Tort; Gerard Urrútia; Miriam Valentini; Yaochen Wang; Richard Peto Journal: Lancet Date: 2013-03-09 Impact factor: 79.321
Authors: Eva M E Balkenende; Taghride Dahhan; Catharina C M Beerendonk; Kathrin Fleischer; Dominic Stoop; Annelies M E Bos; Cornelis B Lambalk; Roel Schats; Jesper M J Smeenk; Leonie A Louwé; Astrid E P Cantineau; Jan Peter de Bruin; Sabine C Linn; Fulco van der Veen; Madelon van Wely; Mariëtte Goddijn Journal: Hum Reprod Date: 2022-07-30 Impact factor: 6.353
Authors: Márcia M Carneiro; Ana M Cota; Maria C Amaral; Moisa L Pedrosa; Bruna O Martins; Marcelo H Furtado; Rivia M Lamaita; Marcia C F Ferreira Journal: JBRA Assist Reprod Date: 2018-09-01